Analysis Ocugen’s Balance Sheet Now Outruns Its Data Calendar — the Science Still Has to Catch Up
Ocugen’s shares rose 4.9% today, extending a run that began with a 16% jump yesterday after the company disclosed progress across two clinical programs alongside its quarterly update. The rally...